Tenax Therapeutics, Inc. — Form 10-K Summary
Period and context: The filing covers the fiscal year ended April 30, 2015, compared with fiscal 2014; it was filed July 14, 2015. This differs from the request metadata’s “2013 Q4.” Tenax was a development-stage specialty pharmaceutical company focused primarily on levosimendan, with no approved drug products for sale.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Total revenue | $49,286 | $158,926 |
| Operating loss | $14.82 million | $16.61 million |
| Net loss | $14.08 million | $19.54 million |
| Net loss per share, basic and diluted | $0.50 | $2.71 |
| Cash used in operations | $9.75 million | $9.26 million |
| Cash and cash equivalents | $7.93 million | $58.32 million |
| Marketable securities | $40.18 million | None reported |
| Working capital | $12.99 million | $56.39 million |
| Total liabilities | $12.48 million | $10.54 million |
| Notes payable, net | $100,160 | $346,890 |
Revenue consisted almost entirely of Army grant reimbursements; product revenue was zero in 2015, versus $25,731 in 2014. Product gross profit was not meaningful: prior-year cost of sales exceeded product revenue. The filing does not provide a useful operating margin given negligible revenue and continuing development-stage losses.
At April 30, 2015, cash plus marketable securities totaled approximately $48.1 million. Management said existing resources were expected to fund operations through calendar 2017, while also stating substantial additional capital would be needed thereafter and for commercialization, if achieved. Accumulated deficit was approximately $150.7 million.
Material changes versus prior year
- Net loss narrowed by about $5.5 million, primarily reflecting lower general and administrative expense and substantially lower interest expense; lower revenue and increased research and development spending partly offset these improvements.
- Research and development expense rose to $6.66 million from $3.00 million, mainly as the Phase III levosimendan program advanced. General and administrative expense fell to $7.17 million from $13.77 million, largely because prior-year stock-based compensation was unusually high.
- Cash and cash equivalents declined substantially, while the company invested proceeds in marketable securities. Investing cash outflow was $40.93 million, primarily reflecting securities purchases.
- Tenax suspended Oxycyte and other perfluorocarbon development, recorded $1.03 million of long-lived-asset impairment, and shifted resources toward levosimendan. Dermacyte sales were discontinued.
- Cash used in operations increased modestly to $9.75 million from $9.26 million. The prior year included a $55 million common-stock offering and other preferred-stock and warrant proceeds; FY 2015 financing cash flow was $0.28 million.
Outlook, programs, and risks
- Levosimendan—cardiac surgery: The LEVO-CTS Phase III trial was underway under an FDA Special Protocol Assessment and Fast Track designation. It was designed as a randomized, double-blind, placebo-controlled study of approximately 760 patients at about 50–60 North American sites. The filing anticipated roughly 24 months for enrollment and completion; it does not report trial results.
- Septic shock: Tenax provided funding to the UK LeoPARDS trial, designed to enroll 516 patients. The company said results could inform development, but the trial was not designed by Tenax and no outcome was reported.
- Commercialization: The company had not selected a commercialization approach and was evaluating licensing, self-commercialization, or a strategic partner. Orion was the sole levosimendan manufacturing source. License terms include regulatory and sales milestones and tiered royalties.
- Funding and execution risks: Tenax had no approved products or product revenue and expected continuing losses. Its runway estimate depends on assumptions; additional financing may be unavailable or dilutive. Clinical delays, unfavorable trial results, regulatory requirements, reimbursement and market acceptance could materially affect prospects.
- Other exposures: Outstanding warrants and options create potential dilution. Product liability insurance for clinical trials was limited to $3 million. The company reported ordinary-course litigation that management did not believe would materially affect the financial statements; no material contingency amount was specified.
- Reporting and unusual items: The auditor gave unqualified opinions on the financial statements and internal controls; management also concluded controls were effective. Tenax changed its fiscal year to calendar year effective January 1, 2016 and planned an eight-month transition report for the period ending December 31, 2015.
Important facts for investors to verify
- Confirm the filing period: this is the fiscal 2015 Form 10-K, not a 2013 fourth-quarter report.
- Check subsequent LEVO-CTS and LeoPARDS enrollment, completion, results, and any FDA feedback; none are reported here.
- Reconcile liquidity and cash-burn assumptions behind management’s calendar-2017 runway estimate, including the maturity profile and liquidity of marketable securities.
- Review the levosimendan license’s milestone, royalty, manufacturing, and termination provisions, and confirm whether any amounts or terms changed after year-end.
- Assess potential dilution from outstanding options and warrants and the company’s need for future financing.